Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
A case-control study found that patients who developed colon cancer, particularly in the proximal colon, were more likely to have taken antibiotics, whereas antibiotic use was not associated with increased risk of rectal cancer.
Researchers analyzed eight studies with 353 patients to assess the effect of low-molecular-weight heparin or warfarin on recanalization, thrombosis progression, and bleeding.
Testing for Clostridioides difficile at one Wisconsin hospital found higher risk for colonization among hematology-oncology patients but an association of residential proximity to livestock farms and colonization only among patients admitted to
Psychological therapies were effective for irritable bowel syndrome (IBS) when delivered in person, whereas therapy that was self-administered, internet-based, or provided with minimal contact did not yield significant benefit.
A meta-analysis didn't find an association between famotidine use and severe disease or death from COVID-19, and the association of these outcomes with proton-pump inhibitors varied by study type.
While the American College of Gastroenterology (ACG) included new recommendations for using fecal microbiota transplantation in recurrent Clostridioides difficile infection, it recommended against the use of probiotics for both primary and secondary
Failure to follow guidelines, diagnostic imaging without alpha-fetoprotein measurement, and diagnosis from an incidental finding were all associated with a delay of more than 60 days between a red flag for hepatocellular carcinoma and a diagnosis, a
The primary outcome of the retrospective cohort study was postcolonoscopy colorectal cancer within three years, defined as colorectal cancer diagnosed within six and 36 months after negative findings on index colonoscopy.
A retrospective trial showed no increase in new corticosteroid therapy or disease-related hospitalization or surgery among patients who discontinued 5-aminosalycilate (5-ASA) therapy when initiating an anti-tumor necrosis factor (anti-TNF) agent.